2 BODALCHEM share price target reports by brokerages below. See what is analyst's view on BODALCHEM share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
Given the future road map in terms of revenue visibility and margin expansion plans in place, by undertaking an aggressive capex plan, we believe that long term story still remains intact. However, in the near term given the slowdown in terms of subdued demand across the end user segment, which is impacting an average realization shall weigh on the performance. In addition, the weak performance from Trion Chemicals (facing technical and safety related issues) would also weigh on overall performance. Though we believe the current valuation of 10.0x/7.5 x FY20E/FY21E earnings, factors in negative news and stock is trading at a fair valuation given the industry dynamics, but we do not foresee improvement in margin (which we had seen in past due to higher realization and return ratios). Hence, we discontinue the coverage on the stock with a SELL rating and revised target price of Rs65 (earlier Rs 71), valuing it at 7x FY21E earnings
The stock is down ~35% since our last report dated 22nd May, 2019 (rating SELL) and at current valuation of 8.1x/7.6X FY20E/FY21E earnings, trading at fair valuation given the industry dynamics (weakness in demand and lower realization as capacity in China ramp-up) and re-rating will take some time. Hence, we continue to retain our SELL rating, with a revised target price of Rs.71 (earlier Rs109), valuing it at 7x FY21E earnings.
Volume growth in SPS, Trion and Thionol Chloride will remain the key growth driver for next two years until the new capacity comes on stream. However, China turbulence can impact realisation growth thereby putting pressure on operating margins. Moreover, any negative surprise on FCF generation due to lower OPM and extension in working capital can impact the payback cycle of upcoming capex. We value the company at EV/EBITDA of 5x and arrive a target price of Rs 105. We have a REDUCE rating on the stock.
Factoring 4QFY19 performance, we have revised our FY20E earnings to Rs12.7 (earlier Rs13) and introducing FY21E with earnings estimate of Rs13.6. The stock is up ~18% since our last report dated 7th Feb, 2019 (rating BUY) and at CMP, we believe that at current valuation of 9.0x/8.4X FY20E/FY21E earnings, the stock is trading at fair valuation and re-rating will take some more time. Hence, we recommend SELL (earlier BUY) on the stock (valuing at 8x FY21E EPS), with a revised target price of Rs109 (earlier Rs117), as we roll forward our valuation multiple to FY21E.
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.